Shots:

• The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis
• WuXi Biologics will be responsible for biologics discovery- process development- and manufacturing- whereas Aravive will be responsible for pre/ clinical development
• In 2018- Aravive and WuXi Biologics expanded their manufacturing collaboration for development and manufacturing of AVB-500 following the US FDA’s IND filing of AVB-500

Click here to­ read full press release/ article | Ref: PRNewswire  | Image: Wuxi Biologics